SG Americas Securities
SVA

SG Americas Securities’s Sinovac Biotech, Ltd SVA Stock Holding History

SG Americas Securities’s Portfolio SVA Stock Details SVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-24,021
Closed -$179K – 3688
2018
Q2 		$179K Hold
24,021
– – ﹤0.01% 2677
2018
Q1 		$207K Buy
24,021
+780
+3% +$6.43K ﹤0.01% 2416
2017
Q4 		$183K Buy
23,241
+100
+0.4% +$748 ﹤0.01% 2508
2017
Q3 		$163K Buy
+23,141
New +$158K ﹤0.01% 2771

Other funds holding SVA

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NAH
Neumann Advisory (HK) Central, Hong Kong $356M AUM 37.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SSP
Sapphire Star Partners Redmond, Washington $74.7M AUM 5.87% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
YMRC
Yorktown Management & Research Company Forest, Virginia $120M AUM 52.72% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
FIM
Freedom Investment Management Hartford, Connecticut $337M AUM 22.95% 1-Year Est. Return

SG Americas Securities's SVA Position: Q3 2018 in Review

SG Americas Securities sold out of Sinovac Biotech, Ltd (SVA) in Q3 2018, closing a stake of 24,021 shares — an estimated $179K sold.

SG Americas Securities first reported a position in SVA in Q3 2017 and held it in 4 quarters. The position peaked at $207K in Q1 2018. 28 funds tracked by Wall St. Rank hold SVA as of Q3 2018.

  • SG Americas Securities reported no remaining Sinovac Biotech, Ltd position as of Q3 2018 after selling out during the quarter.
  • SG Americas Securities sold 24,021 Sinovac Biotech, Ltd shares in Q3 2018, an estimated $179K.
  • SG Americas Securities first reported a position in Sinovac Biotech, Ltd in Q3 2017 and held it in 4 quarters.
  • SG Americas Securities's Sinovac Biotech, Ltd position peaked at $207K in Q1 2018.
  • 28 funds tracked by Wall St. Rank held Sinovac Biotech, Ltd as of Q3 2018.

Based on SG Americas Securities's 13F filing for Q3 2018, filed 6 Nov 2018.